Business
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies Grand Cayman, Cayman Islands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Silexion Therape
About this update from Silexion Therapeutics Corp
[{"type":"image","alt":"Silexion Therapeutics Corp","displaySize":"","headline":null,"caption":"Silexion Therapeutics Corp","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dEbifqbuIRrs3yctodIWKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29","width":300,"height":116}},"lazy":false},{"type":"text","content":"SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models","length":149,"tagName":"p"},{"type":"text","content":"Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform","length":129,"tagName":"p"},{"type":"text","content":"Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies","length":139,"tagName":"p"},{"type":"text","content":"Grand Cayman, Cayman Islands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today released a letter to shareholders from Chairman and Chief Executive Officer, Mr. Ilan Hadar. The letter outlines the Company’s major progress in 2025, including positive preclinical data demonstrating significant inhibition in human KRAS-mutated cancer cell line models, successful completion of regulatory toxicology studies, positive feedback from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on Phase 2/3 trial design, and strategic manufacturing and clinical development collaborations positioning SIL204 for its planned human clinical trial initiation in 2026. In parallel, the letter outlines the vision ahead for 2026 and significant expected near-term milestones.","length":914,"tagName":"p"},{"type":"text","content":"Dear Shareholders,","length":18,"tagName":"p"},{"type":"text","content":"2025 was a transformational year for Silexion Therapeutics. We positioned our lead asset, SIL204, to enter human clinical trials in the first half of 2026, bringing us significantly closer to delive...